Abstract 1458P
Background
Pucotenlimab is a novel anti-PD-1 IgG4 monoclonal antibody. Several clinical trials conducted in China have demonstrated its efficacy and safety in various solid tumors including gastric cancer and breast cancer. Here we report a phase II study result of pucotenlimab for nsq-NSCLC without EGFR/ALK mutations.
Methods
In this open-label phase II study, patients naive to systemic treatment were enrolled with histologically diagnosed stage IIIB or IV nsq-NSCLC. Patients were received intravenous Pucotenlimab 200mg Q3w for up to 35 cycles, combined with platinum + pemetrexed Q3W for 4 cycles and followed by maintenance pemetrexed Q3W (all intravenous). The primary endpoint was overall response rate (ORR) and safety, and the secondary endpoints were progression-free survival (PFS), duration of response (DOR) and overall survival (OS).
Results
From September 25th, 2020 to April 15th, 2021, a total of 43 patients were enrolled and followed up with a median of 13.1 months by the cut-off date (August 3th, 2022). 22 patients achieved partial response and 20 remained stable disease, respectively, contributing an ORR of 48.8% (95%CI: 38.9%, 59.2%) and a DCR of 95.3% (95%CI: 88.7%, 98.4%). The median PFS, DOR were 11.1 months (95%CI: 6.8, 14.4) and 13.9 (95%CI: 6.6, NE) months, respectively. The median OS was not reached. The common treatment-related adverse events (TRAEs) of any grade included anemia (79.1%), neutrophil count decreased (72.1%), white blood cell count decreased (67.4%) and platelet count decrease (53.5%). Neutrophil count decreased (32.6%) was the most reported grade 3/4 TRAE.
Conclusions
Pucotenlimab combined with pemetrexed plus platinum demonstrated promising efficacy and safety for the 1st line nsq-NSCLC patients without EGFR/ALK mutations.
Clinical trial identification
NCT04750083.
Editorial acknowledgement
Legal entity responsible for the study
Taizhou Hanzhong Biomedical Co. Ltd.
Funding
Taizhou Hanzhong Biomedical Co. Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20